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Abstract 28 
The aim of this study was to carry out a systematic review and meta-analysis of the effects of 29 
caffeine supplementation on physiological responses to submaximal exercise. 26 studies met 30 
the inclusion criteria of adopting double-blind, randomised, crossover designs that included a 31 
sustained (5 – 30 minutes) fixed-intensity bout of submaximal exercise (constrained to 60 – 32 
85% V̇O2max) using a standard caffeine dose of 3 – 6 mg·kg
-1
 administered 30 – 90 minutes 33 
prior to exercise. Meta-analyses were completed using a random-effects model, and data are 34 
presented as raw mean difference (D) with associated 95% confidence limits (CL95). Relative 35 
to placebo, caffeine led to significant increases in submaximal measures of minute ventilation 36 
(D = +3.36 L·min
-1
; CL95[+1.63, +5.08]; p = 0.0001; n = 73), blood lactate (D = +0.69 37 
mmol·L
-1
; CL95[+0.46, +0.93]; p < 0.00001; n = 208), and blood glucose (D = +0.42 mmol·L
-
38 
1
; CL95[+0.29, +0.55]; p < 0.00001; n = 129). In contrast, caffeine had a suppressive effect on 39 
ratings of perceived exertion (D = -0.8; CL95[-1.1, -0.6]; p < 0.00001; n = 147). Caffeine had 40 
no effect on measures of heart rate (p = 0.99; n = 207), respiratory exchange ratio (p = 0.18; n 41 
= 181), or V̇O2 (p = 0.92; n = 203).  The positive effects of caffeine supplementation on 42 
sustained high-intensity exercise performance are widely accepted; though the mechanisms to 43 
explain that response are currently unresolved. This meta-analysis has revealed clear effects 44 
of caffeine on various physiological responses during submaximal exercise, which may help 45 
to explain its ergogenic action. 46 
 47 
Key words: Ergogenic aids, methylxanthine, endurance exercise, adenosine receptor.  48 
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Introduction 50 
Caffeine, a trimethylxanthine, is a ubiquitous socially acceptable drug with no apparent long-51 
term health effects.
1
 While there is some evidence that caffeine may improve single
2
 and 52 
repeated sprint activities,
3
 effects are most consistently observed in sustained bouts of high-53 
intensity aerobic exercise.
1
 Typical ergogenic doses of 3 – 6 mg·kg
-1
 ingested 30 – 90 54 
minutes prior to exercise have been shown to result in performance increases of up to 6% in 55 
events lasting from a few minutes to several hours.
1
 The key mechanism by which caffeine is 56 
believed to exert its effect is via the antagonism of adenosine receptors, leading to increases 57 
in neurotransmitter release, motor unit firing rates, and pain suppression.
4
 However, the 58 
ubiquitous nature of adenosine receptors, coupled with their ability to produce differential 59 
responses depending on the site of action and the receptor subtype involved, has made it 60 
difficult to identify the precise mechanisms by which caffeine exerts its ergogenic effect.   61 
 62 
One of the problems with trying to evaluate the mechanisms by which caffeine improves 63 
high-intensity endurance performance is that the associated physiological responses are likely 64 
to be influenced by the increase in exercise intensity responsible for the increase in 65 
performance. Although some studies have attempted to address this problem by including a 66 
fixed-intensity submaximal bout of exercise (generally at around 60 – 85% V̇O2max) prior to a 67 
performance-based test, often as part of a warm-up or when attempting to simulate the steady 68 
state conditions that typically occur in the early stages of endurance events, the results 69 
contain some discrepancies. For example, whilst some studies have found no effect of 70 
caffeine on minute ventilation (V̇E),
5-11
 others have reported a significant increase.
12,13
 71 
Similarly, many studies report no effect of caffeine on respiratory exchange ratio 72 
(RER),
6,8,9,11,13-23
 though some have reported a significant decrease,
10,12,24-26
 and one, a 73 
significant increase.
5
 These discrepancies could easily be attributed to statistical error 74 
resulting from the relatively small sample sizes that are typical of these investigations, and 75 
have often been criticised.
27,28
 The aim of this systematic review and meta-analysis was 76 
therefore to investigate the effects of caffeine suppl mentation on physiological responses to 77 
submaximal exercise.  78 
 79 
Methods 80 
Systematic review 81 
The databases of Pubmed, SportDiscus, Science Direct, and Web of Science were searched 82 
for peer-reviewed publications (prior to September 2015) containing ‘caffeine’ in the title and 83 
any of the following words in the title or the abstract: ‘endurance’, ‘submaximal’, ‘aerobic’, 84 
‘steady state’, ‘exhaustion’, or ‘fixed intensity’. Reference lists of those studies that passed 85 
the initial screening for potential inclusion in the analysis along with those from relevant 86 
review articles
4,27-35
 and textbooks
1
 were also examined for publications which may have 87 
eluded the search of online databases. 88 
 89 
Inclusion and exclusion criteria 90 
Studies considered for inclusion in this investigation were limited to those conducted on adult 91 
(age: ≥ 18 years) humans, which had adopted double-blind, randomised, crossover designs 92 
using a standard effective caffeine dose of 3 – 6 mg·kg
-1
 administered 30 – 90 minutes prior 93 
to exercise. Studies examining combinations of supplements were included in the analysis if 94 
the experimental design incorporated a caffeine versus placebo comparison.
5,25
 In cases 95 
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where studies had investigated the effects of different caffeine doses,
10,13,18,36
 the dose closest 96 
to the upper limit of the inclusion range was used in the analysis. Exercise intensities were 97 
constrained to those required to elicit 60 – 85% V̇O2max, since those intensities span the range 98 
typically experienced in prolonged endurance events,
37
 and as such, were the most commonly 99 
used to evaluate the effects of caffeine on submaximal physiological responses. On those 100 
occasions where studies had investigated the effects of caffeine supplementation on several 101 
exercise intensities,
19,22,26,36,38
 the intensity closest to the middle of the inclusion range was 102 
chosen for the analysis. Exercise duration was limited to a minimum of 5 minutes, to provide 103 
sufficient time for physiological responses to achieve a steady state; and to a maximum of 30 104 
minutes to reduce any effect that fatigue may have on the results. Studies using bouts of 105 
submaximal exercise longer than 30 minutes were included in the analysis if physiological 106 
measurements were made within the 5 – 30 minutes inclusion window. In instances where 107 
authors had made multiple measurements within the 5 – 30 minutes inclusion window, values 108 
closest to the upper limit of 30 minutes were used in the meta-analysis. No inclusion 109 
restrictions were placed on potential moderator variables of gender, training status, caffeine 110 
habituation, or supplementation method, since previous research has failed to establish 111 
whether any of those variables influence the effects of caffeine on endurance performance.
1
 112 
However, subgroup meta-analyses were used to investigate potential influences of 113 
supplementation method and exercise intensity on the physiological responses to caffeine 114 
(see below).   115 
 116 
Data extraction 117 
For the meta-analysis, data were extracted from relevant publications as means, standard 118 
deviations (SD), and sample sizes. In instances where data were presented in a graphical 119 
format, images were enlarged to improve the precision of the data estimates. Physiological 120 
responses were limited to those which were most commonly evaluated during submaximal 121 
exercise, which were: heart rate, oxygen uptake (V̇O2), RER, V̇E, rating of perceived exertion 122 
(RPE), blood lactate concentration [BLa], and blood glucose concentration [BGl]. Measures 123 
of RPE were constrained to those evaluated using the 15-point scale.
39
    124 
 125 
Meta-analysis 126 
From an initial search result of 483 studies, 26 met the inclusion criteria for the meta-analysis 127 
(Table 1). Meta-analyses were conducted using specialist software (Review Manager Version 128 
5.3. The Nordic Cochrane Centre, Copenhagen: The Cochrane Collaboration, 2014). Meta-129 
analyses were completed using a random-effects model and data are presented as raw mean 130 
difference (D) with associated 95% confidence limits (CL95). The choice to use D rather than 131 
a standardized mean difference was based on the fact that each physiological response was 132 
measured on the same scale.
40
 Moreover, the advantage of using D is that it provides an 133 
outcome to the analysis which is intuitively meaningful to the reader.
40
 Heterogeneity 134 
between studies was examined using the I
2 
statistic,
 
which describes the percentage of 135 
variability in mean difference estimates due to heterogeneity rather than chance. When I
2 
was 136 
> 25% (25 – 50% represents moderate heterogeneity
41
),
 
a subgroup meta-analysis was 137 
completed to investigate the source of heterogeneity. In line with recommendations regarding 138 
tests for heterogeneity,
42
 CL95 for I
2
 were calculated using the method outlined by Higgins & 139 
Thompson.
43
 Subgroup meta-analyses were performed, when appropriate, to investigate the 140 
influence of the following potential moderator variables: 1) exercise intensity (constrained to 141 
comparisons between the upper [‘high intensity’] and lower [‘low intensity’] half of the 142 
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inclusion range); and 2) supplementation method (capsule versus drink formats). Of the 143 
remaining potential moderator variables, no comparisons were made to investigate the effects 144 
of: 1) exercise mode: since most had used either cycling (n = 17) or running (n = 5) and there 145 
was no rationale to expect any differential effects of caffeine; 2) gender: since only one study 146 
(2) had used solely female participants; 3) training status: since between-study inconsistences 147 
in the way that this variable was reported/measured did not allow quantification with 148 
adequate precision; 4) caffeine dose: since most studies (n = 21) had used doses of 5 – 6 149 
mg·kg
-1
; and 5) administration time: since most studies had administered the supplement 60 150 
minutes prior to exercise (n = 21). Heterogeneity between subgroups was also evaluated 151 
using the I
2
 statistic. Statistical significance was accepted at p < 0.05 for all analyses. 152 
 153 
Results 154 
Heart rate 155 
Relative to placebo, there was no significant effect of caffeine on heart rate (Figure 1) (D = -156 
0.01 b·min
-1
; CL95[-1.43, +1.42]; p = 0.99; n = 207). There was a moderate degree of 157 
heterogeneity in heart rate responses between the 21 studies included in the analysis (I
2
 = 158 
27%; CL95[0, 57]). Subgroup analyses revealed that there was no evidence of heterogeneity 159 
between studies performed in the upper half of the exercise intensity inclusion range or 160 
between those studies that administered caffeine in a drink format (Table 2). Nevertheless, 161 
there were still no effects of caffeine on heart rate, regardless of subgroup, and there was no 162 
evidence of heterogeneity between subgroups (Table 2). 163 
 164 
Oxygen uptake 165 
The effects of caffeine on V̇O2 during submaximal exercise are presented in Figure 2. 166 
Relative to placebo, caffeine had no significant effect on V̇O2 (D = -0.00 L·min
-1
; CL95[-0.04, 167 
+0.03]; p = 0.92; n = 203) and the level of heterogeneity across the 20 studies that were 168 
analysed was low (I
2
 = 24%; CL95[0, 56]). 169 
 170 
Respiratory exchange ratio 171 
In comparison with placebo, there was no significant effect of caffeine on RER during 172 
submaximal exercise (D = -0.01; CL95[-0.01, 0.00]; p = 0.18; n = 181) (Figure 2). There was, 173 
however, evidence of high heterogeneity between the 18 studies that were analysed (I
2
 = 174 
69%; CL95[50, 81]). Evidence of high between-study heterogeneity remained in each of the 175 
subgroups analysed (Table 2), but there was no evidence of heterogeneity between subgroups 176 
(Table 2).  177 
 178 
Minute ventilation 179 
Eight studies measured the effect of caffeine on V̇E during submaximal exercise, the effects 180 
of which are presented in Figure 2. Relative to placebo, caffeine resulted in a significant 181 
increase in V̇E (D = +3.36 L·min
-1
 [+1.63, +5.08]; p = 0.0001; n = 73), and there was no 182 
evidence of heterogeneity between studies (I
2
 = 0%; CL95[0, 68]). 183 
 184 
Rating of perceived exertion 185 
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In comparison with placebo, caffeine resulted in a significant reduction in RPE (D = -0.8 [-186 
1.1, -0.6]; p < 0.00001; n = 147) during submaximal exercise (Figure 1). There was, however, 187 
evidence of moderate heterogeneity between studies (n = 15) (I
2
 = 35%; CL95[0, 65]). 188 
Subgroup analyses revealed that there was no evidence of heterogeneity between studies 189 
performed in the lower half of the exercise intensity inclusion range or between studies that 190 
administered caffeine in a capsule format (Table 2). Nevertheless, there was no evidence of 191 
heterogeneity between subgroups and the effect of caffeine on RPE remained regardless of 192 
any subgroup heterogeneity (Table 2),    193 
 194 
Blood lactate 195 
The effect of caffeine on [BLa] is presented in Figure 3. Relative to placebo, caffeine resulted 196 
in a significant increase in [BLa] (D = +0.69 mmol·L
-1
 [+0.46, +0.93]; p < 0.00001; n = 208). 197 
However, there was evidence of high heterogeneity between the 21 studies that met the 198 
inclusion criteria (I
2
 = 74%; CL95[60, 83]). Evidence of high heterogeneity remained in all 199 
subgroup analyses; though the significant effect of caffeine on [BLa] was lost in the subgroup 200 
that administered caffeine in a drink format and there was evidence of high heterogeneity 201 
between the supplementation method subgroups (Table 2).  202 
 203 
Blood glucose 204 
In comparison with placebo, there was a significant increase in [BGl] (D = +0.42 mmol·L
-1
 205 
[+0.29, +0.55]; p < 0.00001; n = 129) following caffeine supplementation (Figure 3). There 206 
was, however, evidence of high heterogeneity between the 15 studies analysed (I
2
 = 75%; 207 
CL95[59, 85]) and there was evidence of heterogeneity in each of the subgroups (Table 2). 208 
Nevertheless, the significant effect of caffeine on [BGl] remained in each subgroup, though 209 
there was evidence of moderate heterogeneity between the exercise intensity subgroups 210 
(Table 2).        211 
 212 
Discussion 213 
The aim of this study was to carry out a systematic review and meta-analysis of the effects of 214 
caffeine supplementation on physiological responses to submaximal exercise. The key 215 
findings were that caffeine supplementation resulted in significant increases in V̇E, [BLa], 216 
and [BGl]. In contrast, caffeine had a significant suppressive effect on RPE, and no effect on 217 
heart rate, RER, or V̇O2. Despite similar methodological approaches adopted by the studies 218 
included in the meta-analysis, there were several instances of moderate to high heterogeneity; 219 
although, in several instances, the confidence limits suggest a large degree of uncertainty in 220 
the true magnitude of that heterogeneity. Nevertheless, apart from the [BLa] response in the 221 
subgroup that administered caffeine in a drink format, the effects of caffeine on the above 222 
physiological responses remained regardless of any heterogeneity and the effects of 223 
heterogeneity could not be explained by between-study differences in exercise intensity or 224 
supplementation method.  225 
 226 
The key mechanism by which caffeine is believed to interact with human tissue, and thereby 227 
influence endurance performance, is via the antagonism of adenosine receptors.
4,31
 If this is 228 
the case, it should be possible to resolve all of the responses determined in this meta-analysis 229 
by that mechanism. Adenosine is a ubiquitous endogenous extracellular signalling molecule, 230 
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the concentration of which increases during exercise due to the hydrolysis of adenosine 231 
triphosphate.
44,45
 Adenosine exerts its effect via its interaction with G-protein coupled cell 232 
membrane receptors, widely expressed throughout the body, and of which there are four 233 
subtypes (A1, A2A, A2B, and A3).
44,45
 Although adenosine has the highest affinity for the A1 234 
and A2A receptor subtypes,
45
 the ability of adenosine receptors to activate and inhibit the 235 
same signalling cascades
44,45
 has made it difficult to identify the precise mechanism by which 236 
adenosine exerts its effects. Nevertheless, there is evidence that adenosine signalling affects 237 
glucose homeostasis and lipid metabolism,
44
 central nervous system function,
46
 and 238 
cardiovascular and respiratory responses;
47
 all of which could explain the physiological 239 
responses observed in this meta-analysis. 240 
 241 
During exercise, [BLa] is determined from the balance between lactate production and 242 
clearance; with approximately 70 – 80% of the latter achieved via oxidation, and the 243 
remainder by gluconeogenesis.
48
 As such, the caffeine-induced increase in [BLa] determined 244 
in this meta-analysis could be due to either an increase in lactate production (via glycolysis) 245 
or an impairment of clearance. Although there is some evidence that adenosine signalling can 246 
inhibit glycolysis via a corresponding reduction in insulin sensitivity,
49-51
 there is no evidence 247 
that caffeine antagonises this response. Indeed, despite an increase in [BLa], Graham et al.
17
 248 
was unable to detect any effect of caffeine on lactate release from active muscle. Moreover, 249 
in a subsequent meta-analysis, Graham et al.
28
 found no effect of caffeine on post-exercise 250 
(10 – 15 mins at 70-85% V̇O2max) muscle glycogen concentrations. Similar difficulties exist 251 
when trying to explain the increase in [BLa] by a possible impairment of lactate clearance, in 252 
that whilst there is evidence that adenosine signalling increases gluconeogenesis, caffeine 253 
does not appear to impair this process; at least not when determined from the rate of post-254 
exercise [BLa] clearance.
52
 In short, at present, despite a clear effect of caffeine on [BLa] 255 
during submaximal exercise, the mechanisms to explain that response remain unresolved. 256 
 257 
As with [BLa], the effects of caffeine on [BGl] can be explained by a mismatch between 258 
production and clearance. In the case of clearance, there is evidence that adenosine facilitates 259 
intracellular glucose transport, via insulin-dependent and independent mechanisms.
53
 260 
Moreover, while there are likewise many contradictory reports,
44
 there is also evidence that 261 
caffeine antagonises that response.
54
 In contrast, the idea that caffeine may increase [BGl] by 262 
facilitating an increase in hepatic glucose release seems much less likely; indeed, there is 263 
some evidence that adenosine may even increase hepatic glycogenolysis via A1 receptor 264 
signalling.
44
 In short, a caffeine-facilitated impairment of glucose clearance provides the most 265 
likely mechanism to explain the increase in [BGl] determined in this meta-analysis. 266 
 267 
One finding from this meta-analysis that is particularly difficult to explain is the lack of any 268 
effect of caffeine on RER. Goedecke et al.
55
 reported a strong positive correlation (r = 0.63) 269 
between RER and [BLa] during exercise at 70% V̇O2max. As such, it is surprising that despite 270 
the fact that caffeine supplementation resulted in a significant increase in [BLa], there was no 271 
corresponding increase in RER; in fact, the pattern of the response was towards a reduction in 272 
RER. Nevertheless, caffeine did result in an increase in V̇E,, a response which could be 273 
explained by the buffering response associated with the disruption of acid-base balance, as 274 
indicated by the caffeine-induced increase in [BLa].
56
 Then again, it is possible to explain the 275 
increase in V̇E by a direct stimulatory effect of caffeine, particularly since caffeine is reported 276 
to lower the sensitivity threshold of central chemoreceptors for CO2;
57
 moreover, the fact that 277 
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adenosine has differential effects on V̇E depending on the type of adenosine receptor 278 
affected,
58
 suggests that the response is most likely due to the effect of caffeine on the A1 279 
receptor subtype.
58
 Either way, given that at least part of the caffeine-induced increase in V̇E 280 
is likely due to the drive to reduce CO2, it is difficult to explain how, in the absence of any 281 
corresponding change in V̇O2, that response does not affect RER. 282 
 283 
Although this meta-analysis revealed no effect of caffeine on heart rate, it is difficult to 284 
reconcile that response with adenosine receptor antagonism, given that adenosine is reported 285 
to increase heart rate,
47,59
 most likely by reducing parasympathetic and increasing cardiac 286 
sympathetic nervous system tone.
59
 However, exogenous adenosine infusions have been 287 
shown to have differential effects on heart rate depending on the dose and the site of 288 
infusion.
47
 Moreover, while there is evidence of a small caffeine-induced reduction in resting 289 
heart rate,
31,52
 that effect is reported to dissipate as exercise intensity increases,
52
 supporting 290 
the findings of this meta-analysis. Nevertheless, and as previously reported,
30
 caffeine did 291 
lead to a reduction in RPE, a response which could be explained by the fact that adenosine 292 
has be shown to increase pain, at least in animal models, and most likely via interaction with 293 
A2B receptors.
60
 However, given that the RPE scale was developed to reflect also the heart 294 
rate response to exercise,
39
 the findings of this meta-analysis suggest that caffeine may 295 
uncouple that relationship.   296 
 297 
Although the effects of caffeine as an adenosine receptor antagonist can explain most of the 298 
effects determined in this meta-analysis, there are instances where, depending on the receptor 299 
subtype involved, adenosine can elicit contrasting effects to those highlighted above. 300 
However, given the clear effects of caffeine on most of the physiological responses 301 
examined, it seems unlikely that those effects are important, at least during the exercise 302 
conditions examined in this meta-analysis. Finally, it is worth noting that despite the clear 303 
effects of caffeine determined in this meta-analysis, there were many instances where studies 304 
were unable to detect those effects, most likely due to issues associated with relatively small 305 
sample sizes. 306 
 307 
Conclusion 308 
The results of this meta-analysis reveal clear effects of caffeine on [BLa], [BGl], V̇E, and 309 
RPE during submaximal exercise, independent of any ergogenic response. While those 310 
effects can be explained by the antagonistic effects of caffeine on adenosine receptors, 311 
differential effects of adenosine on the various receptor subtypes make it difficult to identify 312 
the precise mechanisms by which adenosine, and therefore caffeine, influences human 313 
physiology. Nevertheless, it is envisaged that the results of this meta-analysis will help to 314 
distinguish caffeine-induced physiological responses from those associated with 315 
corresponding increases in submaximal endurance performance and, as such, help future 316 
researchers to identify the most likely mechanisms by which caffeine exerts its ergogenic 317 
effect.  318 
 319 
Practical Applications 320 
The positive effects of caffeine supplementation on endurance performance are well-321 
established; particularly when consumed in a dose of 3 – 6 mg·kg
-1
 ingested 30 – 90 minutes 322 
prior to exercise.
1
 Those performance improvements are accompanied by various 323 
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physiological responses associated with the corresponding increase in exercise intensity, 324 
making it difficult to distinguish performance- from caffeine-related effects. This meta-325 
analysis has revealed clear effects of caffeine on measures of [BLa], [BGl], V̇E, and RPE, 326 
independent of any ergogenic effect, which, given its dietary prevalence, reinforces the 327 
importance of caffeine restriction prior to any experimental intervention or physiological 328 
profile. For researchers, the results of this meta-analysis reinforce the problems associated 329 
with the use of small sample sizes, with several instances where individual investigations 330 
failed to find significant effects despite clear evidence to the contrary. 331 
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Figure Legends 478 
Figure 1. Forest plots of studies that have investigated the effects of caffeine 479 
supplementation on heart rate (upper plot) and ratings of perceived exertion (lower plot) 480 
during sustained (5 – 30 minutes) fixed-intensity (60 – 85% V̇O2max) submaximal exercise. 481 
Squares represent the raw mean difference, relative to placebo, with associated 95% 482 
confidence limits. The size of each square reflects the weighting given to the response. The 483 
diamond at the base of each plot represents the overall effect calculated from a random 484 
effects model; the width of the diamond representing the 95% confidence interval. 485 
 486 
Figure 2. Forest plots of studies that have investigated the effects of caffeine 487 
supplementation on oxygen uptake (upper plot), respiratory exchange ratio (middle plot), and 488 
minute ventilation (lower plot) during sustained (5 – 30 minutes) fixed-intensity (60 – 85% 489 
V̇O2max) submaximal exercise. Squares represent the raw mean difference, relative to placebo, 490 
with associated 95% confidence limits. The size of each square reflects the weighting given 491 
to the response. The diamond at the base of each plot represents the overall effect calculated 492 
from a random effects model; the width of the diamond representing the 95% confidence 493 
interval.  494 
 495 
Figure 3. Forest plots of studies that have investigated the effects of caffeine 496 
supplementation on blood lactate (upper plot) and blood glucose (lower plot) concentrations 497 
during sustained (5 – 30 minutes) fixed-intensity (60 – 85% V̇O2max) submaximal exercise. 498 
Squares represent the raw mean difference, relative to placebo, with associated 95% 499 
confidence limits. The size of each square reflects the weighting given to the response. The 500 
diamond at the base of each plot represents the overall effect calculated from a random 501 
effects model; the width of the diamond representing the 95% confidence interval. 502 
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Table 1. The effects of caffeine supplementation (3-6 mg∙kg-1), administered 30 – 90 minutes prior to a sustained (≥ 5 minutes) fixed-intensity bout of submaximal (60 
– 85% V)O2max) exercise, on selected physiological responses.   
Author(s) n Exercise 
mode 
Exercise duration and 
intensity   
Training status Gender Dose (mg∙kg
-1
) Pre-test supplementation 
time (mins) 
Supplementation 
method 
Physiological responses
*  
Acker-Hewitt et al.
5
  10 Cycling 20 mins @ 60% V)O2max Cyclists M 6  60  Capsule ↑ RER; no ∆ in [BGl], [BLa], HR, RPE, V)E, or V)O2   
Anderson et al.
6 
8 Rowing 6 mins @ ~74% V)O2max Rowers F 6  60  Capsule no ∆ in [BLa], HR, RER, RPE, V)E, or V)O2  
Bell & McLellan
14 
13
 
Cycling 80% V)O2max to exh Active  M&F 5  60 Capsule ↑ [BGl]
††
, [BLa]
††
, HR, & V)O2; ↓ RPE; no ∆ in RER  
Bell & McLellan
14 
8
† 
Cycling 80% V)O2max to exh Active  M&F 5  60 Capsule ↑ [BGl], [BLa], HR, & V)O2; ↓ RPE; no ∆ in RER  
Bell et al.
7 
8 Cycling 85% V)O2max to exh Healthy M 5  90  Capsule ↑ [BLa] , no ∆ in [BGl], HR, RPE, V)E, or V)O2   
Black et al.
15 
14 Cycling 30 mins @ 60% V)O2max Active  M&F 5  60  Capsule ↑ [BLa]; no ∆ in HR, RPE, RER, or V)O2  
Black et al.
15 
14 Arm cranking 30 mins @ 60% V)O2max Active  M&F 5  60  Capsule ↑ [BLa]; no ∆ in HR, RPE, RER, or V)O2  
Bruce et al.
8
  8 Rowing 6 mins @ 75% V)O2max  Rowers M 6  60  Capsule no ∆ in HR, RER, RPE, V)E, or V)O2  
Casal & Leon
9 
9 Running 45 mins @ 75% V)O2max Runners M ~6 (400 mg) 60  Drink
‡
 no ∆ in HR, RER, RPE, V)E, or V)O2  
Costill et al.
24 
9 Cycling 80% V)O2max to exh Cyclists M&F ~5 (330 mg) 60  Drink
‡
 ↓ RER & RPE; no ∆ in [BGl], [BLa], HR, or V)O2   
Cruz et al.
12 
8 Cycling ~73% V)O2max to exh Active M 6  60  Capsule ↑ [BGl], [BLa], V)E; ↓ RER; no ∆ in HR, or V)O2   
Daniels et al.
61 
10 Cycling 55 mins @ 65% V)O2max Cyclists M&F 6  45  Capsule no ∆ in HR   
Demura et al.
16 
10 Cycling 60 mins @ 60% V)O2max Healthy M 6  60  Drink
‡
 ↓ RPE; no ∆ in [BLa], HR, RER, or V)O2   
Doherty et al.
38 
11 Cycling 6 mins @ 70% V)O2max Cyclists M 5  60  Drink
**
 no ∆ in HR or RPE  
Giles & Maclaren
25 
6 Running 120 mins @ 65% V)O2max Runners M 5  60  Drink
‡
 ↑ V)O2; ↓ RER & RPE; no ∆ in [BGl], or [BLa]  
Graham & Spriet
18 
8 Running 85% V)O2max to exh Runners M 6  60  Capsule ↑ [BGl]; no ∆ in [BLa], RER, or V)O2  
Graham et al.
62 
9 Running 85% V)O2max to exh Runners M&F 4.45  60  Capsule no ∆ in [BGl] or [BLa]  
Graham et al.
62 
9 Running 85% V)O2max to exh Runners M&F 4.45  60  Drink
‡
 no ∆ in [BGl] or [BLa]  
Graham et al.
17 
10 Cycling 60 mins @ 70% V)O2max Healthy M 6  60  Capsule ↑ [BGl] & [BLa],; no ∆ in HR, RER, or V)O2  
Greer et al.
19 
7 Cycling 45 mins @ 70% V)O2max Active M 6  90  Capsule no ∆ in [BGl], [BLa], RER, or V)O2  
Jenkins et al.
13 
13 Cycling 15 mins @ 80% V)O2max Cyclists M 3   60 Capsule ↑ [BLa] & V)E; no ∆ in HR, RER, or V)O2   
McClaran & Wetter
10 
9 Cycling 5 mins @ ~63% V)O2max Active M 3  30  Capsule ↓ HR & RER; no ∆ in RPE, V)E, or V)O2   
Olcina et al.
20 
20 Cycling 30 mins @ 75% V)O2max Untrained M 5  60 Capsule no ∆ in [BLa], RER, or V)O2  
Roy et al.
21 
12 Cycling 60 mins @ 65% V)O2max Trained M&F 6  75 Capsule ↑ [BLa]; no ∆ in [BGl], HR, RER, or V)O2  
Stadheim et al.
26 
10 X-C skiing 5 mins @ 70% V)O2max  X-C skiers M 6  ~60 Drink
**
 ↑ [BGl]; ↓ RER & RPE; no ∆ in [BLa], HR, or V)O2   
Stadheim et al.
36 
8 X-C skiing 5 mins @ 65% V)O2max X-C skiers M 4.5  ~60 Drink
**
 ↑ [BLa]; ↓ RPE; no ∆ in HR, or V)O2   
Tarnopolsky et al.
11
  6 Running 90 mins @ 70% V)O2max Runners M 6   60 Drink
**
 no ∆ in [BGl], [BLa], HR, RER, RPE, V)E, or V)O2  
Toner et al.
22 
8 Cycling 5 mins @ 73.2% V)O2max Mixed M ~4.6 (350 mg) 60 Drink
‡
 no ∆ in HR, RER, or V)O2  
Van Soeren & Graham
23 
6 Cycling 85% V)O2max to exh Active M 6  60 Capsule no ∆ in [BGl], [BLa], RER, or V)O2  
Note: [BGl] = blood glucose concentration; [BLa] = blood lactate concentration; HR = heart rate; RER = respiratory exchange ratio; RPE = rating of perceived exertion; V)E = minute 
ventilation; V)O2 = rate of oxygen consumption; V)O2max = maximal rate of oxygen consumption; exh = exhaustion; X-C = cross country; M = male; F = female; ↑ = significant (p < 0.05) 
increase relative to placebo; ↓ = significant (p < 0.05) decrease relative to placebo; no ∆ = no significant (p ≥ 0.05) change relative to placebo;* = all measurements made within the first 
30 minutes of exercise; † = caﬀeine naive; ‡ = dose added to decaﬀeinated coﬀee; ** = dose added to arOﬁcially sweetened water/lemonade/juice; †† = based on a sample size of 11; 
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Table 2. Summary of subgroup meta-analyses examining the possible influence of exercise intensity (low intensity: 60 – 72.5% V#O2max vs high intensity: 72.5 
– 85% V#O2max) and supplementation method (capsule vs drink formats) on the effect of caffeine supplementation on various physiological responses during 
fixed-intensity (60 – 85% V#O2max) submaximal exercise. 
Responses No of studies Sample size Mean difference p Heterogeneity I
2
 (%) 
Subgroup differences 
I
2
 (%) p 
Heart rate (b.min
-1
)        
 Low intensity 13 132 -0.57 [-2.81, +1.68] 0.62 47 [0, 72] 
0 0.33 
 High intensity 8 75 +0.83 [-0.88, +2.54] 0.34 0 [0, 68] 
 Capsule 14 145 -0.02 [-2.08, +2.03] 0.98 45 [0, 71] 
0 0.79 
 Drink 7 62 -0.40 [-2.38, +1.58] 0.69 0 [0, 71] 
Respiratory exchange ratio        
 Low intensity 11 109 -0.00 [-0.02, +0.01] 0.58 67 [38, 83] 
0 0.92 
 High intensity 7 72 -0.01 [-0.02, 0.00] 0.32 64 [18, 84] 
 Capsule 12 132 -0.00 [-0.01, +0.01] 0.42 50 [3, 74] 
0 0.57 
 Drink 6 49 -0.01 [-0.03, +0.01] 0.27 84 [67, 92] 
Ratings of perceived exertion        
 Low intensity 9 92 -0.8 [-1.0, -0.6] < 0.00001 0 [0, 65] 
0 0.78 
 High intensity 6 55 -0.9 [-1.6, -0.2] 0.02 64 [13, 85] 
 Capsule 8 84 -0.8 [-1.1, -0.4] 0.0001 0 [0, 68] 
0 0.65 
 Drink 7 63 -0.9 [-1.2, -0.5] < 0.00001 59 [5, 82] 
Blood lactate (mmol·L
-1
)        
 Low intensity 12 116 +0.64 [+0.40, +0.88] < 0.00001 64 [33, 81] 
0 0.70 
 High intensity 9 92 +0.76 [+0.22, +1.30] 0.006 83 [69, 91] 
 Capsule 15 159 +0.87 [+0.62, +1.12] < 0.00001 55 [19, 75] 
80 0.02 
 Drink 6 49 +0.33 [-0.07, +0.73] 0.11 82 [62, 92] 
Blood glucose (mmol·L
-1
)        
 Low intensity 7 62 +0.32 [+0.15, +0.49] 0.0002 72 [39, 87] 
49 0.16 
 High intensity 8 67 +0.51 [+0.31, +0.71] < 0.00001 68 [33, 85] 
 Capsule 11 98 +0.42 [+0.25, +0.59] < 0.00001 78 [61, 88] 
0 0.90 
 Drink 4 31 +0.40 [+0.20, +0.60] 0.0001 41 [0, 80] 
Note: Values in square parentheses represent 95% confidence limits 
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Study or Subgroup
Acker-Hewitt et al. (2012)
Anderson et al. (2000)
Bell & McLellan (2002)
Bell & McLellan (2002)
Bell et al. (1998)
Black et al. (2015)
Black et al. (2015)
Bruce et al. (2000)
Casal & Leon (1985)
Cruz et al. (2015)
Daniels et al. (1998)
Demura et al. (2007)
Doherty et al. (2004)
Graham et al. (2000)
Jenkins et al. (2008)
McClaran & Wetter (2007)
Roy et al. (2001)
Stadheim et al. (2013)
Stadheim et al. (2014)
Tarnopolsky et al. (1989)
Toner et al. (1982)
Total (95% CI)
Heterogeneity: Tau² = 2.53; Chi² = 27.22, df = 20 (P = 0.13); I² = 27%
Test for overall effect: Z = 0.01 (P = 0.99)
Mean
140
153
169
174
181
156
146
161
149.8
161.9
132.5
146.7
141
158
181
146
146
156
142.7
157.3
152
SD
6
9
10
8
9
11
12
11
8.1
3.6
13.9
10.8
18
4
3.4
3.5
11
4
3.4
6.5
12
Total
10
8
13
8
8
14
14
8
9
8
10
10
11
10
13
9
12
10
8
6
8
207
Mean
146
152
167
172
177
161
141
159
149.1
163.5
146
144.1
146
154
179
148
145
156
144.6
153.3
153
SD
8
6
8
10
10
7
10
8
8.1
3.1
10.9
9.3
12
4
3.1
4
11
3
3.4
7.7
10
Total
10
8
13
8
8
14
14
8
9
8
10
10
11
10
13
9
12
10
8
6
8
207
Weight
4.2%
3.1%
3.5%
2.3%
2.1%
3.6%
2.7%
2.1%
3.1%
9.9%
1.6%
2.3%
1.2%
9.3%
12.8%
9.4%
2.3%
10.5%
9.8%
2.7%
1.6%
100.0%
IV, Random, 95% CI
-6.00 [-12.20, 0.20]
1.00 [-6.50, 8.50]
2.00 [-4.96, 8.96]
2.00 [-6.87, 10.87]
4.00 [-5.32, 13.32]
-5.00 [-11.83, 1.83]
5.00 [-3.18, 13.18]
2.00 [-7.43, 11.43]
0.70 [-6.78, 8.18]
-1.60 [-4.89, 1.69]
-13.50 [-24.45, -2.55]
2.60 [-6.23, 11.43]
-5.00 [-17.78, 7.78]
4.00 [0.49, 7.51]
2.00 [-0.50, 4.50]
-2.00 [-5.47, 1.47]
1.00 [-7.80, 9.80]
0.00 [-3.10, 3.10]
-1.90 [-5.23, 1.43]
4.00 [-4.06, 12.06]
-1.00 [-11.82, 9.82]
-0.01 [-1.43, 1.42]
Caffeine Placebo Mean Difference Mean Difference
IV, Random, 95% CI
-20 -10 0 10 20
Favors Placebo Favors Caffeine
Study or Subgroup
Acker-Hewitt et al. (2012)
Anderson et al. (2000)
Bell & McLellan (2002)
Bell & McLellan (2002)
Black et al. (2015)
Black et al. (2015)
Bruce et al. (2000)
Casal & Leon (1985)
Costill et al. (1978)
Demura et al. (2007)
Doherty et al. (2004)
Giles & MacLaren (1984)
McClaran & Wetter (2007)
Stadheim et al. (2013)
Stadheim et al. (2014)
Total (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 21.69, df = 14 (P = 0.09); I² = 35%
Test for overall effect: Z = 6.53 (P < 0.00001)
Mean
11.3
11.1
15.4
16.2
12.6
13.4
10.8
11.7
12.1
15
12.5
10.5
13.4
14.1
11.8
SD
1.4
1.9
1.3
1.4
1.3
1
2.4
0.5
0.8
1.3
1.3
0.6
1
0.3
0.4
Total
10
8
8
13
14
14
8
9
9
10
11
6
9
10
8
147
Mean
11.7
10.8
16.8
17
14.1
14
11.2
12.1
14.1
15.6
12.7
11.7
13.8
14.8
12.8
SD
0.8
1.3
0.8
2
1.2
1.4
2.5
0.5
1
1.2
1.6
0.5
0.9
0.3
0.5
Total
10
8
8
13
14
14
8
9
9
10
11
6
9
10
8
147
Weight
4.8%
2.2%
4.4%
3.0%
5.4%
5.7%
1.0%
12.8%
6.3%
4.2%
3.5%
9.3%
5.9%
18.3%
13.2%
100.0%
IV, Random, 95% CI
-0.40 [-1.40, 0.60]
0.30 [-1.30, 1.90]
-1.40 [-2.46, -0.34]
-0.80 [-2.13, 0.53]
-1.50 [-2.43, -0.57]
-0.60 [-1.50, 0.30]
-0.40 [-2.80, 2.00]
-0.40 [-0.86, 0.06]
-2.00 [-2.84, -1.16]
-0.60 [-1.70, 0.50]
-0.20 [-1.42, 1.02]
-1.20 [-1.82, -0.58]
-0.40 [-1.28, 0.48]
-0.70 [-0.96, -0.44]
-1.00 [-1.44, -0.56]
-0.82 [-1.07, -0.58]
Caffeine Placebo Mean Difference Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favors Placebo Favors Caffeine
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Study or Subgroup
Acker-Hewitt et al. (2012)
Anderson et al. (2000)
Bell & McLellan (2002)
Bell & McLellan (2002)
Bell et al. (1998)
Black et al. (2015)
Black et al. (2015)
Bruce et al. (2000)
Casal & Leon (1985)
Costill et al. (1978)
Cruz et al. (2015)
Demura et al. (2007)
Graham et al. (2000)
Jenkins et al. (2008)
McClaran & Wetter (2007)
Olcina et al.(2008)
Stadheim et al. (2013)
Stadheim et al. (2014)
Tarnopolsky et al. (1989)
Toner et al. (1982)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 25.17, df = 19 (P = 0.16); I² = 24%
Test for overall effect: Z = 0.10 (P = 0.92)
Mean
3.23
2.3
3.1
3.44
3.27
1.88
1.39
3.56
2.93
3.34
2.72
1.95
3.14
3.84
2.66
2.26
3.18
3.13
4.44
2.96
SD
0.4
0.41
0.9
0.71
0.34
0.22
0.28
0.31
0.06
0.18
0.12
0.33
0.08
0.05
0.27
0.47
0.07
0.08
0.21
0.15
Total
10
8
8
13
8
14
14
8
9
9
8
10
10
13
9
20
10
8
6
8
203
Mean
3.41
2.2
3.01
3.39
3.28
1.89
1.37
3.51
2.97
3.24
2.72
1.87
3.11
3.78
2.58
2.26
3.28
3.19
4.31
3.05
SD
0.36
0.94
0.73
0.75
0.41
0.27
0.28
0.39
0.06
0.15
0.13
0.35
0.09
0.05
0.27
0.53
0.14
0.06
0.15
0.15
Total
10
8
8
13
8
14
14
8
9
9
8
10
10
13
9
20
10
8
6
8
203
Weight
1.0%
0.2%
0.2%
0.4%
0.8%
3.1%
2.5%
0.9%
15.9%
4.2%
6.1%
1.3%
11.9%
20.2%
1.8%
1.2%
8.5%
12.9%
2.5%
4.5%
100.0%
IV, Random, 95% CI
-0.18 [-0.51, 0.15]
0.10 [-0.61, 0.81]
0.09 [-0.71, 0.89]
0.05 [-0.51, 0.61]
-0.01 [-0.38, 0.36]
-0.01 [-0.19, 0.17]
0.02 [-0.19, 0.23]
0.05 [-0.30, 0.40]
-0.04 [-0.10, 0.02]
0.10 [-0.05, 0.25]
0.00 [-0.12, 0.12]
0.08 [-0.22, 0.38]
0.03 [-0.04, 0.10]
0.06 [0.02, 0.10]
0.08 [-0.17, 0.33]
0.00 [-0.31, 0.31]
-0.10 [-0.20, -0.00]
-0.06 [-0.13, 0.01]
0.13 [-0.08, 0.34]
-0.09 [-0.24, 0.06]
-0.00 [-0.04, 0.03]
Caffeine Placebo Mean Difference Mean Difference
IV, Random, 95% CI
-0.5 -0.25 0 0.25 0.5
Favors Placebo Favors Caffeine
Study or Subgroup
Acker-Hewitt et al. (2012)
Anderson et al. (2000)
Black et al. (2015)
Black et al. (2015)
Bruce et al. (2000)
Casal & Leon (1985)
Cruz et al. (2015)
Demura et al. (2007)
Giles & MacLaren (1984)
Graham et al. (2000)
Jenkins et al. (2008)
McClaran & Wetter (2007)
Olcina et al.(2008)
Roy et al. (2001)
Stadheim et al. (2013)
Tarnopolsky et al. (1989)
Toner et al. (1982)
Van Soeren & Graham (1998)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 54.75, df = 17 (P < 0.00001); I² = 69%
Test for overall effect: Z = 1.33 (P = 0.18)
Mean
0.96
0.84
0.97
0.94
0.94
0.85
0.93
0.95
0.85
0.93
0.99
0.93
1.09
0.94
0.96
0.97
0.94
0.83
SD
0.07
0.04
0.06
0.03
0.09
0.01
0.02
0.04
0.04
0.03
0.01
0.03
0.13
0.04
0.01
0.01
0.05
0.01
Total
10
8
14
14
8
9
8
10
6
10
13
9
20
12
10
6
8
6
181
Mean
0.89
0.89
0.96
0.93
0.98
0.84
0.95
0.95
0.92
0.94
0.99
0.94
1.14
0.93
0.98
0.97
0.94
0.84
SD
0.03
0.06
0.07
0.05
0.12
0.01
0.02
0.04
0.03
0.04
0.001
0.03
0.14
0.03
0.01
0.02
0.05
0.01
Total
10
8
14
14
8
9
8
10
6
10
13
9
20
12
10
6
8
6
181
Weight
2.7%
2.5%
2.6%
4.9%
0.7%
10.9%
7.6%
4.1%
3.5%
4.9%
11.8%
5.5%
1.0%
5.4%
11.0%
8.2%
2.5%
10.2%
100.0%
IV, Random, 95% CI
0.07 [0.02, 0.12]
-0.05 [-0.10, -0.00]
0.01 [-0.04, 0.06]
0.01 [-0.02, 0.04]
-0.04 [-0.14, 0.06]
0.01 [0.00, 0.02]
-0.02 [-0.04, -0.00]
0.00 [-0.04, 0.04]
-0.07 [-0.11, -0.03]
-0.01 [-0.04, 0.02]
0.00 [-0.01, 0.01]
-0.01 [-0.04, 0.02]
-0.05 [-0.13, 0.03]
0.01 [-0.02, 0.04]
-0.02 [-0.03, -0.01]
0.00 [-0.02, 0.02]
0.00 [-0.05, 0.05]
-0.01 [-0.02, 0.00]
-0.01 [-0.01, 0.00]
Caffeine Placebo Mean Difference Mean Difference
IV, Random, 95% CI
-0.1 -0.05 0 0.05 0.1
Favors Placebo Favors Caffeine
Study or Subgroup
Acker-Hewitt et al. (2012)
Anderson et al. (2000)
Bell et al. (1998)
Bruce et al. (2000)
Casal & Leon (1985)
Cruz et al. (2015)
Jenkins et al. (2008)
McClaran & Wetter (2007)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 4.48, df = 7 (P = 0.72); I² = 0%
Test for overall effect: Z = 3.81 (P = 0.0001)
Mean
77.4
53.8
108.5
99
81.8
80
104.7
59.5
SD
15.9
6.1
17.7
17
3.4
3.6
5.5
6
Total
10
8
8
8
9
8
13
9
73
Mean
74.4
51.7
108.9
94
80
76.2
97.9
56.6
SD
11.8
6.1
13.5
19
3
4.3
4.8
3.4
Total
10
8
8
8
9
8
13
9
73
Weight
2.0%
8.4%
1.3%
1.0%
34.0%
19.8%
19.0%
14.7%
100.0%
IV, Random, 95% CI
3.00 [-9.27, 15.27]
2.10 [-3.88, 8.08]
-0.40 [-15.83, 15.03]
5.00 [-12.67, 22.67]
1.80 [-1.16, 4.76]
3.80 [-0.09, 7.69]
6.80 [2.83, 10.77]
2.90 [-1.61, 7.41]
3.36 [1.63, 5.08]
Caffeine Placebo Mean Difference Mean Difference
IV, Random, 95% CI
-20 -10 0 10 20
Favors Placebo Favors Caffeine
Page 17 of 18
Human Kinetics, 1607 N Market St, Champaign, IL 61825
International Journal of Sports Physiology and Performance
For Peer Review
 
 
 
 
Study or Subgroup
Acker-Hewitt et al. (2012)
Bell & McLellan (2002)
Bell & McLellan (2002)
Bell et al. (1998)
Black et al. (2015)
Black et al. (2015)
Cruz et al. (2015)
Demura et al. (2007)
Giles & MacLaren (1984)
Graham & Spriet (1995)
Graham et al. (1998)
Graham et al. (1998)
Graham et al. (2000)
Greer et al. (2000)
Jenkins et al. (2008)
Olcina et al.(2008)
Roy et al. (2001)
Stadheim et al. (2013)
Stadheim et al. (2014)
Tarnopolsky et al. (1989)
Van Soeren & Graham (1998)
Total (95% CI)
Heterogeneity: Tau² = 0.18; Chi² = 77.14, df = 20 (P < 0.00001); I² = 74%
Test for overall effect: Z = 5.76 (P < 0.00001)
Mean
2.17
5.7
5.4
9
3.7
4.5
7.55
4.7
3.62
4.26
2.8
2.9
3.17
4.14
9.7
4.12
3.75
3.5
2.42
2.58
4.6
SD
0.4
1.8
1.2
0.7
1
1.4
0.52
1.75
0.62
0.69
0.3
0.6
0.45
0.65
0.7
1.82
2.15
0.25
0.32
0.35
0.9
Total
10
8
11
8
14
14
8
10
6
8
9
9
10
8
13
20
12
10
8
6
6
208
Mean
1.75
4.6
5.3
7.75
3
3.4
6.01
4.9
2.78
3.66
3.1
2.4
2.2
3.78
8.2
3.92
2.9
3.15
1.53
2.48
3.1
SD
0.5
1.7
1.7
0.5
1
1
0.47
2.29
0.83
0.64
0.6
0.3
0.24
0.59
0.7
1.95
1.6
0.29
0.21
0.26
0.6
Total
10
8
11
8
14
14
8
10
6
8
9
9
10
8
13
20
12
10
8
6
6
208
Weight
6.5%
1.5%
2.5%
5.3%
4.4%
3.7%
5.9%
1.4%
4.0%
4.9%
6.2%
6.2%
6.9%
5.2%
5.6%
2.7%
1.9%
7.3%
7.2%
6.8%
3.8%
100.0%
IV, Random, 95% CI
0.42 [0.02, 0.82]
1.10 [-0.62, 2.82]
0.10 [-1.13, 1.33]
1.25 [0.65, 1.85]
0.70 [-0.04, 1.44]
1.10 [0.20, 2.00]
1.54 [1.05, 2.03]
-0.20 [-1.99, 1.59]
0.84 [0.01, 1.67]
0.60 [-0.05, 1.25]
-0.30 [-0.74, 0.14]
0.50 [0.06, 0.94]
0.97 [0.65, 1.29]
0.36 [-0.25, 0.97]
1.50 [0.96, 2.04]
0.20 [-0.97, 1.37]
0.85 [-0.67, 2.37]
0.35 [0.11, 0.59]
0.89 [0.62, 1.16]
0.10 [-0.25, 0.45]
1.50 [0.63, 2.37]
0.69 [0.46, 0.93]
Caffeine Placebo Mean Difference Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favors Placebo Favors Caffeine
Study or Subgroup
Acker-Hewitt et al. (2012)
Bell & McLellan (2002)
Bell & McLellan (2002)
Bell et al. (1998)
Cruz et al. (2015)
Giles & MacLaren (1984)
Graham & Spriet (1995)
Graham et al. (1998)
Graham et al. (1998)
Graham et al. (2000)
Greer et al. (2000)
Roy et al. (2001)
Stadheim et al. (2013)
Tarnopolsky et al. (1989)
Van Soeren & Graham (1998)
Total (95% CI)
Heterogeneity: Tau² = 0.04; Chi² = 55.50, df = 14 (P < 0.00001); I² = 75%
Test for overall effect: Z = 6.36 (P < 0.00001)
Mean
4.3
3.1
4
4.73
4.42
4.68
5.89
4.3
4.7
5.57
3.85
5.6
4.8
5.19
3.89
SD
0.49
0.5
0.5
0.11
0.28
0.69
0.41
0.5
0.5
0.15
0.27
0.65
0.1
0.36
0.22
Total
10
11
8
8
8
6
8
9
9
10
8
12
10
6
6
129
Mean
4.16
3.2
3.3
4.23
3.92
4.2
4.74
4
4.3
5.07
3.84
5.45
4.5
4.5
3.5
SD
0.53
0.7
0.3
0.09
0.28
0.63
0.25
0.4
0.5
0.15
0.14
0.65
0.1
0.21
0.52
Total
10
11
8
8
8
6
8
9
9
10
8
12
10
6
6
129
Weight
5.0%
4.2%
5.6%
11.3%
7.8%
2.4%
6.7%
5.3%
4.8%
10.7%
9.1%
4.1%
11.4%
6.7%
4.9%
100.0%
IV, Random, 95% CI
0.14 [-0.31, 0.59]
-0.10 [-0.61, 0.41]
0.70 [0.30, 1.10]
0.50 [0.40, 0.60]
0.50 [0.23, 0.77]
0.48 [-0.27, 1.23]
1.15 [0.82, 1.48]
0.30 [-0.12, 0.72]
0.40 [-0.06, 0.86]
0.50 [0.37, 0.63]
0.01 [-0.20, 0.22]
0.15 [-0.37, 0.67]
0.30 [0.21, 0.39]
0.69 [0.36, 1.02]
0.39 [-0.06, 0.84]
0.42 [0.29, 0.55]
Caffeine Placebo Mean Difference Mean Difference
IV, Random, 95% CI
-1 -0.5 0 0.5 1
Favors Placebo Favors Caffeine
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